Antiviral Therapy

Papers
(The TQCC of Antiviral Therapy is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
A baseline model including quantitative anti-HBc to predict response of peginterferon in HBeAg-positive chronic hepatitis B patients31
Commentary: Development of Therapeutics for Congenital Cytomegalovirus Infection27
HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective20
Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting17
The making of the one pill—Developing single tablet regimens for HIV and for HCV15
Abacavir safety and effectiveness in young infants with HIV in South African observational cohorts14
Retrospective chart review of transplant recipients with cytomegalovirus infection who received maribavir in the Phase 3 SOLSTICE trial: Data at 52 weeks post-maribavir treatment initiation14
Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants13
Cost-effectiveness of tenofovir alafenamide fumarate for treatment of chronic hepatitis B: Evidence from a tertiary hospital in Vietnam13
Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: A prospective real-world clinical study10
Commentary: John C. Martin (1951–2021)10
A rare complication of coronary vasospasm associated with concomitant use of ergotamine, cobicistat, and darunavir10
In-silico approach to characterize the structure and function of a hypothetical protein of Monkeypox virus exploring Chordopox-A20R domain-containing protein activity9
Tenofovir alafenamide fumarate9
RVX-208, an inducer of Apolipoprotein A-I, inhibits the particle production of hepatitis B virus through activation of cGAS-STING pathway8
Seroprevalence, seroconversion, and mother-to-child transmission of dual and triplex infections of HIV, HBV, and HCV among Nigerian obstetric population: A national multicentre prospective cohort stud7
A favipiravir-induced angioedema and urticaria in a COVID-19 patient7
Dolutegravir and rilpivirine as successful initial antiretroviral therapy in a treatment-naive patient with HIV-1: A case report7
The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir7
The evolution of clinical study design in heavily treatment-experienced persons with HIV: A critical review6
Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis6
Andrographolide suppresses SARS-CoV-2 infection by downregulating ACE2 expression: A mechanistic study6
Computer-assisted drug discovery of potential natural inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase through a multi-phase in silico approach6
Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical s5
The transformation of HIV therapy: One pill once a day5
Durability of multi-drug antiretroviral therapy (mega-ART) in treatment-experienced people with HIV in the ARCA database5
The diagnostic significance of the C-reactive protein (CRP) in HIV/TB coinfection: A systematic review and meta-analysis5
0.034704923629761